全文获取类型
收费全文 | 224364篇 |
免费 | 20990篇 |
国内免费 | 14467篇 |
专业分类
耳鼻咽喉 | 1752篇 |
儿科学 | 2671篇 |
妇产科学 | 2572篇 |
基础医学 | 31227篇 |
口腔科学 | 4039篇 |
临床医学 | 28339篇 |
内科学 | 31993篇 |
皮肤病学 | 2327篇 |
神经病学 | 11330篇 |
特种医学 | 7906篇 |
外国民族医学 | 121篇 |
外科学 | 21484篇 |
综合类 | 37486篇 |
现状与发展 | 58篇 |
一般理论 | 15篇 |
预防医学 | 14870篇 |
眼科学 | 5830篇 |
药学 | 24926篇 |
184篇 | |
中国医学 | 12378篇 |
肿瘤学 | 18313篇 |
出版年
2024年 | 848篇 |
2023年 | 3640篇 |
2022年 | 9057篇 |
2021年 | 11344篇 |
2020年 | 8399篇 |
2019年 | 7418篇 |
2018年 | 7723篇 |
2017年 | 7138篇 |
2016年 | 6678篇 |
2015年 | 9965篇 |
2014年 | 12216篇 |
2013年 | 11374篇 |
2012年 | 16330篇 |
2011年 | 17819篇 |
2010年 | 11847篇 |
2009年 | 9431篇 |
2008年 | 11589篇 |
2007年 | 11857篇 |
2006年 | 11153篇 |
2005年 | 10616篇 |
2004年 | 7566篇 |
2003年 | 7233篇 |
2002年 | 6217篇 |
2001年 | 5239篇 |
2000年 | 4993篇 |
1999年 | 5010篇 |
1998年 | 3244篇 |
1997年 | 3292篇 |
1996年 | 2403篇 |
1995年 | 2202篇 |
1994年 | 1938篇 |
1993年 | 1345篇 |
1992年 | 1647篇 |
1991年 | 1476篇 |
1990年 | 1316篇 |
1989年 | 1176篇 |
1988年 | 1033篇 |
1987年 | 897篇 |
1986年 | 764篇 |
1985年 | 609篇 |
1984年 | 459篇 |
1983年 | 374篇 |
1982年 | 306篇 |
1981年 | 273篇 |
1980年 | 225篇 |
1979年 | 227篇 |
1978年 | 192篇 |
1977年 | 211篇 |
1976年 | 191篇 |
1974年 | 156篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
33.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
34.
35.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
36.
Eric S. Zhou Larissa Nekhlyudov Sharon L. Bober 《Translational andrology and urology》2015,4(2):218-231
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples. 相似文献
37.
目的 探讨剂量组学在预测肺癌根治性放疗患者放射性肺炎发生中的应用潜能。方法 回顾性收集行根治性放疗的314例肺癌患者的临床资料、放疗剂量文件、定位及随访CT图像,根据临床资料及影像学随访资料对放射性肺炎进行分级,提取全肺的剂量组学特征,构建机器学习模型。应用1000次自助抽样法(bootstrap)的最小绝对值收敛和选择算子嵌套逻辑回归(LASSO‐LR)及1000次bootstrap的赤池信息量准则(AIC)向后法筛选与放射性肺炎相关的剂量组学特征,随机按照7∶3划分为训练集及验证集,应用逻辑回归建立预测模型,并应用ROC曲线及校正曲线评价模型的性能。结果 共提取120个剂量组学特征,经LASSO‐LR降维筛选得到12个特征进入“特征池”,再经过AIC向后法筛选,最终筛选出6个剂量组学特征进行模型构建,训练集AUC为0.77(95%CI为0.65~0.87),独立验证集AUC为0.72(95%CI为0.64~0.81)。结论 利用剂量组学建立的预测模型具有预测放射性肺炎发生的潜力,但仍需继续纳入多中心数据及前瞻性数据进一步挖掘剂量组学的应用潜能。 相似文献
38.
39.
骨碎补是历代临床常用中药,具有疗伤止痛、补肾强骨、消风祛斑等功效。其主要含黄酮、苯丙素、三萜、酚酸及其苷等类化学成分,现代研究表明骨碎补具有抗骨质疏松、促进骨折愈合、促软骨再生、护牙健齿、保护肾功能、抗炎、防治中毒性耳聋、降血脂等多种生物活性,开发前景广阔。本文对近年来骨碎补的化学成分、药理作用及临床应用研究进行综述,以期为骨碎补的进一步深入系统的研究和开发利用提供依据。 相似文献
40.